Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Research

Background:

• Hypercholesterolaemia management remains a challenge, with persistent high cardiovascular (CV) mortality and morbidity despite statin use.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, represent a novel class of lipid-lowering agents.
• These PCSK9 inhibitors are approved in the UK for specific patient groups, including familial hypercholesterolaemia and high CV risk.

Purpose of the Study:

• To evaluate the real-world efficacy of PCSK9 inhibitors (alirocumab and evolocumab) in routine clinical practice.
• To assess the tolerability and effectiveness of these novel lipid-lowering agents in a UK patient cohort.
• To understand the clinical utility of PCSK9 inhibitors beyond clinical trial settings.

Main Methods:

• Retrospective review of patient records from a large health board in Scotland.
• Analysis of data for patients prescribed alirocumab or evolocumab for hypercholesterolaemia.
• Assessment of lipid-lowering efficacy and treatment tolerability in a real-world setting.

Main Results:

• PCSK9 inhibitors demonstrated significant lipid-lowering effects in the studied patient population.
• The real-world tolerability profile of alirocumab and evolocumab was evaluated.
• Efficacy and safety data were collected from routine clinical care settings.

Conclusions:

• PCSK9 inhibitors are effective in reducing cholesterol levels in a real-world UK population.
• These agents appear to be generally well-tolerated in routine clinical use.
• PCSK9 inhibitors offer a valuable therapeutic option for managing hypercholesterolaemia in high-risk patients.